U.S. District Court Issues Favorable Decision for IQVIA Against Veeva
10 May 2021 - 10:00PM
Business Wire
Court ruled that Veeva intended to commit
fraud; destroyed evidence; engaged in theft, and cover-up
IQVIA (NYSE:IQV), a global provider of advanced analytics,
technology solutions, and clinical research services to the life
sciences industry, today announced that the U.S. District Court of
New Jersey issued a favorable decision in its litigation with Veeva
Systems, Inc. (NYSE:VEEV). The Court ruled on IQVIA’s motion for
sanctions, finding Veeva engaged in massive destruction of
evidence, engaged in a cover-up of its wrong-doing, and repeatedly
lied about its actions. The court sanctioned Veeva five separate
times in the decision to punish Veeva for its violations of rules
in the litigation, including multiple adverse jury instructions,
limitations on the use of evidence at trial and an award of legal
fees and costs. Specific language from the decision includes:
Engaging Fraud &
Destruction of Evidence “IQVIA has made a prima facie
showing that Veeva was engaging or intended to engage in a crime
or fraud at the time the DataDestroyed Spreadsheet was created
and that the DataDestroyed Spreadsheet was used in furtherance of
the alleged crime or fraud – namely, the spoliation of
evidence.”
Veeva
Misappropriation of IQVIA Intellectual Property “[T]here
is no dispute that IQVIA Reference Data was “programmatically”
included in Veeva OpenData.”
Theft &
Intentional Cover-Up “The OpenData Data Corruption Memo
indicates that Veeva was well-aware that it was misappropriating
IQVIA data, something the [independent] Audit would uncover,
and that the incident could lead to litigation. Rather than
disclose the allegedly “minor” [client] Incident to IQVIA or the
auditors, Veeva chose to cover it up, deleting evidence and
directing employees not to create further evidence on the subject
(such as replacing “IMS” with “***” in e-mails, not discussing the
situation in chats or e-mails, and deleting chats or e-mails where
the incident was discussed).”
“We are pleased with the Court’s decision, which exposes Veeva’s
longstanding deceptive business practices, as well as its pattern
of corporate theft,” said Harvey Ashman, senior vice president,
deputy general counsel, IQVIA. “Veeva stole IQVIA intellectual
property from client files, they knew it was wrong, they destroyed
evidence to cover-up their wrongdoing, and then they lied about it.
Veeva lied to IQVIA, the court, their clients, the media, and
investors. Veeva’s disregard for intellectual property rights,
contractual obligations, and the truth is clear. IQVIA looks
forward to successfully resolving our ongoing litigation for the
benefit of our clients and reaffirming protections for intellectual
property, innovation, and investment.”
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced
analytics, technology solutions, and clinical research services to
the life sciences industry. IQVIA creates intelligent connections
across all aspects of healthcare through its analytics,
transformative technology, big data resources and extensive domain
expertise. IQVIA Connected Intelligence™ delivers powerful insights
with speed and agility — enabling customers to accelerate the
clinical development and commercialization of innovative medical
treatments that improve healthcare outcomes for patients. With
approximately 72,000 employees, IQVIA conducts operations in more
than 100 countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing information on a scale that helps
healthcare stakeholders identify disease patterns and correlate
with the precise treatment path and therapy needed for better
outcomes. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders tap
into a deeper understanding of diseases, human behaviors, and
scientific advances, to advance their path toward cures. To learn
more, visit www.iqvia.com.
IQVIAFIN
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210510005448/en/
Tor Constantino, IQVIA Media Relations
(tor.constantino@iqvia.com) +1.484.567.6732
Nick Childs, IQVIA Investor Relations (Nchilds@us.imshealth.com)
+1.973.316.3828
IQVIA (NYSE:IQV)
Historical Stock Chart
From Apr 2024 to May 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From May 2023 to May 2024